ArticleNaunyn-Schmiedeberg's archives of pharmacology2004
Protease-activated receptor-2-mediated contraction of urinary bladder is enhanced in cyclophosphamide-treated rats.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- F16357, a novel protease-activated receptor 1 antagonist, improves urodynamic parameters in a rat model of interstitial cystitis.British journal of pharmacology · 2016Article
- Evidence for the role of mast cells in colon-bladder cross organ sensitization.Autonomic neuroscience : basic & clinical · 2013Article
- Role of mast cells and protease-activated receptor-2 in cyclooxygenase-2 expression in urothelial cells.American journal of physiology. Regulatory, integrative and comparative physiology · 2009Article
- Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors.Naunyn-Schmiedeberg's archives of pharmacology · 2008Review
- Loss of prostaglandin E2 release from immortalized urothelial cells obtained from interstitial cystitis patient bladders.American journal of physiology. Renal physiology · 2008Article
- Mandatory role of proteinase-activated receptor 1 in experimental bladder inflammation.BMC physiology · 2007Article
- Proteinase-activated receptors in the lower urinary tract.Naunyn-Schmiedeberg's archives of pharmacology · 2007Review
- TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications.Naunyn-Schmiedeberg's archives of pharmacology · 2006Review
- Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.British journal of pharmacology · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protease-activated receptor-2 (PAR-2) is activated by serine proteases, such as trypsin and mast cell tryptase. Recently, we have shown that activators of PAR-2 contract the rat urinary bladder mainly by stimulating release of prostaglandins (PGs) from the mucosal layer. In the present study, we investigated how the PAR-2-mediated responses are altered in rats with cyclophosphamide (CYP)-induced cystitis. The contractile responses to trypsin and PAR-2 activating peptide (PAR-2 AP; SLIGRL-NH2) in the urinary bladders were augmented by treatment of rats with CYP. The contractile effects of these PAR-2 activators on the smooth muscles of the urinary bladder were also potentiated after induction of cystitis by CYP. On the other hand, CYP-induced cystitis significantly attenuated contractions produced by PGE2 in the smooth muscles of the urinary bladder. The PAR-2-mediated contractions were significantly prevented by indomethacin or NS-398, an inhibitor of cyclooxygenase-2. Both trypsin and PAR-2 AP increased the release of PGE2 from the urinary bladder mucosa and smooth muscle. CYP-induced cystitis enhanced the PAR-2 activators-induced PGE2 releases from the urinary mucosa without affecting those from the smooth muscle of the urinary bladder. The PGE2 releases were prevented by indomethacin or NS-398. The mRNAs for PAR-2 in the urinary bladder mucosa and smooth muscle preparations were not altered in CYP-induced cystitis. These results suggest that PAR-2-mediated responses were enhanced in bladders from CYP-treated rats. The enhancement of PAR-2-mediated contraction might be ascribed to the increased production of PGs and the altered sensitivity of smooth muscle to PAR-2 activators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.